Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Study Objectives:
- To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel
and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell
Carcinoma of the Head and Neck (SCCHN)
- To determine the response rate of the recommended dose
- To determine the safety and tolerability of the recommended dose